Patents Assigned to SCT II LLC
-
Patent number: 11786503Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: GrantFiled: October 7, 2021Date of Patent: October 17, 2023Assignees: Auransa Inc., SCT II LLCInventors: Christopher G. Armstrong, Kevin J. Kim, Lisa Maria Lucia Pham, Eunhye Park, Zhong Zhong, Guanyi Huang, Joseph C. Wu, Sidney Paul Elmer, Viwat Visuthikraisee, Eithon Michael G. Cadag, Thomas Bernard Freeman, Pek Yee Lum
-
Publication number: 20220133684Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: ApplicationFiled: October 7, 2021Publication date: May 5, 2022Applicants: Auransa Inc., SCT II LLCInventors: Christopher G. ARMSTRONG, Kevin J. KIM, Lisa Maria Lucia PHAM, Eunhye PARK, Zhong ZHONG, Guanyi HUANG, Joseph C. WU, Sidney Paul ELMER, Viwat VISUTHIKRAISEE, Eithon Michael G. CADAG, Thomas Bernard FREEMAN, Pek Yee LUM
-
Patent number: 11166936Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: GrantFiled: October 6, 2020Date of Patent: November 9, 2021Assignees: Auransa Inc., SCT II LLCInventors: Christopher G. Armstrong, Kevin J. Kim, Lisa Maria Lucia Pham, Eunhye Park, Zhong Zhong, Guanyi Huang, Joseph C. Wu, Sidney Paul Elmer, Viwat Visuthikraisee, Eithon Michael G. Cadag, Thomas Bernard Freeman, Pek Yee Lum
-
Publication number: 20210121436Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: ApplicationFiled: October 6, 2020Publication date: April 29, 2021Applicants: Auransa Inc., SCT II LLCInventors: Christopher G. ARMSTRONG, Kevin J. KIM, Lisa Maria Lucia PHAM, Eunhye PARK, Zhong ZHONG, Guanyi HUANG, Joseph C. WU, Sidney Paul ELMER, Viwat VISUTHIKRAISEE, Eithon Michael G. CADAG, Thomas Bernard FREEMAN, Pek Yee LUM
-
Patent number: 10874633Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: GrantFiled: January 8, 2020Date of Patent: December 29, 2020Assignees: Auransa Inc., SCT II LLCInventors: Christopher G. Armstrong, Kevin J. Kim, Lisa Maria Lucia Pham, Eunhye Park, Zhong Zhong, Guanyi Huang, Joseph C. Wu, Sidney Paul Elmer, Viwat Visuthikraisee, Eithon Michael G. Cadag, Thomas Bernard Freeman, Pek Yee Lum
-
Patent number: 10806716Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: GrantFiled: February 3, 2017Date of Patent: October 20, 2020Assignees: Auransa Inc., SCT II LLCInventors: Christopher G. Armstrong, Kevin J. Kim, Lisa Maria Lucia Pham, Eunhye Park, Zhong Zhong, Guanyi Huang, Joseph C. Wu, Sidney Paul Elmer, Viwat Visuthikraisee, Eithon Michael G. Cadag, Thomas Bernard Freeman, Pek Yee Lum
-
Publication number: 20200253920Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: ApplicationFiled: January 8, 2020Publication date: August 13, 2020Applicants: Auransa Inc., SCT II LLCInventors: Christopher G. ARMSTRONG, Kevin J. KIM, Lisa Maria Lucia PHAM, Eunhye PARK, Zhong ZHONG, Guanyi HUANG, Joseph C. WU, Sidney Paul ELMER, Viwat VISUTHIKRAISEE, Eithon Michael G. CADAG, Thomas Bernard FREEMAN, Pek Yee LUM
-
Publication number: 20190175544Abstract: This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3?,4?,5?-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).Type: ApplicationFiled: February 3, 2017Publication date: June 13, 2019Applicants: SCT II LLC, Auransa Inc.Inventors: Christopher G. Armstrong, Kevin J. Kim, Lisa Maria Lucia Pham, Eunhye Park, Zhong Zhong, Guanyi Huang, Joseph C. Wu, Sidney Paul Elmer, Viwat Visuthikraisee, Eithon Michael G. Cadag, Thomas Bernard Freeman, Pek Yee Lum